# A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine

> **NCT06608199** · PHASE3 · RECRUITING · sponsor: **Beijing Minhai Biotechnology Co., Ltd** · enrollment: 500 (estimated)

## Conditions studied

- Pneumococcal Vaccines
- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** pneumococcal disease prevention

## Key facts

- **NCT ID:** NCT06608199
- **Lead sponsor:** Beijing Minhai Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608199, "A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06608199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*